BioSpace News Archive

Business

Algernon Pharmaceuticals Announces Appointment of Harry Bloomfield, QC. as a New Board Director and Chairman

Algernon Pharmaceuticals Inc. is pleased to announce that Harry Bloomfield, QC. has been appointed as a new member of the Board of Directors and has been elected Chairman of the Board.

September 9, 2021
·
4 min read
Biotech Bay

ASLAN Pharmaceuticals to Present at H.C. Wainwright 23rd Annual Global Investment Conference

ASLAN Pharmaceuticals today announced Dr Carl Firth, CEO, is scheduled to give a company presentation at the H.C. Wainwright 23rd Annual Global Investment Conference on 13 September, 2021.

September 9, 2021
·
1 min read
Drug Development

Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma (B-NHL) Published in The Lancet

AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) today announced The Lancet published the results of the dose escalation part of the Phase 1/2 EPCORE™ NHL-1 first-in-human (FIH) dose escalation and cohort expansion clinical trial evaluating safety and preliminary efficacy of the investigational therapy epcoritamab (DuoBody®-CD3xCD20) in patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL).

September 9, 2021
·
10 min read
Pharm Country

iECURE Launches With $50 Million Series A Financing to Develop In Vivo Gene Insertion Approaches for Devastating Diseases

iECURE today announced it has closed a $50 million Series A financing led by Versant Ventures and OrbiMed Advisors.

September 9, 2021
·
5 min read
Bio NC

Precision BioSciences Outlines Clinical Development Strategy for In Vivo Gene Editing Pipeline

Precision BioSciences today provided strategic business updates on its in vivo gene editing pipeline during the Company’s first gene editing R&D event.

September 9, 2021
·
16 min read
Drug Development

Fixed-Dose Combination of Albuterol and Budesonide (PT027) Demonstrated Significant Benefits for Asthma Patients in MANDALA and DENALI Phase III Trials

Positive high-level results from the MANDALA and DENALI Phase III trials of PT027.

September 9, 2021
·
8 min read
NeoGenomics’ Liquid Biopsy Subsidiary Inivata and Collaborators to Present Data that Further Validate the Application of its RaDaR(TM) MRD and InVisionFirst(R)-Lung Assays at the ESMO Congress 2021

NeoGenomics, Inc. today announced that its liquid biopsy focused subsidiary Inivata Limited alongside collaborators, will present new data on its RaDaR assay for the detection of molecular residual disease (MRD) and recurrence and on its InVisionFirst-Lung liquid biopsy test at the European Society on September 16-21, 2021.

September 9, 2021
·
7 min read
Lexaria to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Lexaria Bioscience Corp. announces today that Chairman & CEO Chris Bunka will present at the 23rd Annual H.C. Wainwright Global Investment Conference which is being held virtually from September 13-15, 2021.

September 9, 2021
·
3 min read
ZyVersa Therapeutics’ CEO, Stephen C. Glover Invited Panel Member at Inflammasome Therapeutics Summit 2021

ZyVersa is pleased to announce that Stephen C. Glover, ZyVersa’s Co-Founder, Chief Executive Officer, and Chairman, is an invited panel member at the Inflammasome Therapeutics Summit 2021.

September 9, 2021
·
1 min read
Biotech Bay

Evommune Inc., Completes $83 Million Series A Financing to Advance Development of Unique Chronic Inflammation Pipeline

Evommune, Inc. today announced the completion of an $83 million Series A financing which included Andera Partners nd LSP, who joined forces with a global syndicate of investors and existing investor, Pivotal bioVenture Partners.

September 9, 2021
·
3 min read